Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy

Cytokine release syndrome (CRS) is the most common toxicity induced by chimeric antigen receptor (CAR) T cell therapy. At present, anti-IL-6 agents including tocilizumab and siltuximab have been applied in the treatment of CRS. However, tocilizumab and siltuximab are expensive and some patients fail...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lina, Wang, Shuai, Xu, Ji, Zhang, Run, Zhu, Han, Wu, Yujie, Zhu, Liying, Li, Jianyong, Chen, Lijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893957/
https://www.ncbi.nlm.nih.gov/pubmed/33608054
http://dx.doi.org/10.1186/s40164-021-00209-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893957/
https://www.ncbi.nlm.nih.gov/pubmed/33608054
http://dx.doi.org/10.1186/s40164-021-00209-2

Ejemplares similares